David Ternant - Publications

Analysis of the relationship between body composition and the pharmacokinetics of panitumumab in the treatment of localized squamous cell carcinoma of the anus - An ancillary study of the FFCD0904 phase I and II trial.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: December 04, 2025

Cerebral diffusion of posaconazole in an experimental model of disseminated scedosporiosis.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: September 16, 2025

A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: July 08, 2025

Immunoglobulin G Receptors (FcγR), in Addition to Target-Antigen and Neonatal Fc Receptor (FcRn), Influence Rituximab Pharmacokinetics.

Journal: Clinical pharmacokinetics

Published: July 06, 2025

Author's reply: "Personalized bevacizumab dosing in metastatic colorectal cancer: Statistical considerations for a phase III randomized trial".

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: May 31, 2025

Quality Assessment of Therapeutic Drug Monitoring Assays of Therapeutic Antibodies Across Europe: An Update.

Journal: Basic & clinical pharmacology & toxicology

Published: May 23, 2025

Clinical usefulness of anti-α3Gal immunoglobulin E assays for cetuximab-mediated anaphylaxis in head and neck cancer.

Journal: Immuno-oncology technology

Published: March 19, 2025

Comparison of rituximab induction and maintenance regimens in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: PK/PD modelling of ANCA and gammaglobulin levels in real-world patients.

Journal: EBioMedicine

Published: March 18, 2025

Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial).

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: February 09, 2025

Eculizumab dose tapering should take into account the nonlinearity of its pharmacokinetics.

Journal: British journal of clinical pharmacology

Published: October 18, 2023

Population pharmacokinetics of mycophenolate in patients treated for interstitial lung disease (EVER-ILD study).

Journal: Fundamental & clinical pharmacology

Published: October 12, 2023

Confounding mitigation for the exposure-response relationship of bevacizumab in colorectal cancer patients.

Journal: British journal of clinical pharmacology

Published: September 25, 2023